Tag: Nasdaq:ATAI

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

atai Life Sciences Announces $50 Million Private Placement Financing

Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1

Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:ATAI

Remittix Confirms Q3 2025 Beta Wallet Launch with Solana and Ethereum Support, Presale Surpasses $17.3 Million

Remittix Announces Q3 2025 Beta Wallet Launch with Solana Network Support, Raising Over $17.3 Million in Ongoing Presale

No KYC. 100x Leverage. Double Deposit Bonus Match. Crypto Futures Trading Made Easy on BexBack.

Tag: Nasdaq:ATAI

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

atai Life Sciences Announces $50 Million Private Placement Financing

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us